Asia-Pacific long-acting bronchodilator market is anticipated to grow at a substantial rate of 4.5% during the forecast period. Major factors that augment the growth of the market include a large population base susceptible to asthma and COPD, rising awareness about treatment for asthma and COPD, and the significant presence of market players in the region. Asia-Pacific has a potential market due to the increasing R&D and investments by major pharmaceutical companies in pharma and life science research coupled with harnessing innovation. The long-acting bronchodilator market in the Asia-Pacific region presents future opportunities for growth as the prevalence of respiratory diseases such as asthma, COPD in emerging economies such as India and China. In addition, increasing the geriatric population specially in Japan is another major reason for the growing market.

Request a Free Sample of our Report on Asia-Pacific Long-Acting Bronchodilator Market: https://www.omrglobal.com/request-sample/asia-pacific-long-acting-bronchodilator-market  

Asia-Pacific long-acting bronchodilator market is segmented on the basis of route of administration, application, and end-user. Based on the route of administration, the market is classified into oral, nasal, parenteral, and inhalation. Moreover, on the basis of application, the market has been classified into asthma and COPD diseases. The asthma disease application segment dominated the regional market in 2018 and is further estimated to follow the same trend over the forecast period. This is mainly due to the increasing pool of aging population susceptible to the high prevalence of asthma in the economies of the region such as China and India. 

A full Report of Asia-Pacific Long-Acting Bronchodilator Market is Available at: https://www.omrglobal.com/industry-reports/asia-pacific-long-acting-bronchodilator-market

Furthermore, the market is characterized by the presence of several manufacturers that are developing and providing long-acting bronchodilator to cater to a wide range of customers within and outside the region. The major players of the Asia-Pacific long-acting bronchodilator market include Cipla Ltd., AstraZeneca PLC, Beximo Pharmaceuticals Ltd., GlaxoSmithKline PLC, Novartis AG, Teva Pharmaceuticals Industries Ltd., and Teijin Pharma Ltd. These players adopt various strategies to capitalize on market growth opportunities. Mergers and acquisitions, product launch, geographical expansion, partnerships, and collaborations are the majorly adopted strategies by the market players. 

Market Segmentation

Asia-Pacific Long-Acting Bronchodilator Market by Route of Administration 

• Oral
• Nasal
• Parenteral
• Inhalation

Asia-Pacific Long-Acting Bronchodilator Market by Application

• Asthma 
• Chronic Obstructive Pulmonary Disease (COPD)

Asia-Pacific Long-Acting Bronchodilator Market by End-User

• Homecare
• Hospitals and Clinics 

Regional Analysis

• China
• Japan
• India
• Rest of Asia-Pacific

Company Profiles

• Adamis Pharmaceuticals Corp.
• AstraZeneca PLC
• Beximo Pharmaceuticals Ltd.
• Boehringer Ingelheim International GmbH
• Cipla Ltd.
• GlaxoSmithKline PLC
• Novartis AG
• ResMed Corp.
• Pulmatrix Inc.
• Sunovion Pharmaceuticals
• Teijin Pharma Ltd.
• Teva Pharmaceuticals Industries Ltd.

 For More Customized Data, Request for Report Customization @ https://www.omrglobal.com/report-customization/asia-pacific-long-acting-bronchodilator-market

About Orion Market Research

Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.

Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: info@omrglobal.com 
Contact no: +1 646-755-7667, +91 780-304-0404